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Abstract
In metabolomics, identification of complex diseases is often based on application of (multivariate) statistical techniques to
the data. Commonly, each disease requires its own specific diagnostic model, separating healthy and diseased individuals,
which is not very practical in a diagnostic setting. Additionally, for orphan diseases such models cannot be constructed due
to a lack of available data. An alternative approach adapted from industrial process control is proposed in this study:
statistical health monitoring (SHM). In SHM the metabolic profile of an individual is compared to that of healthy people in a
multivariate manner. Abnormal metabolite concentrations, or abnormal patterns of concentrations, are indicated by the
method. Subsequently, this biomarker can be used for diagnosis. A tremendous advantage here is that only data of healthy
people is required to construct the model. The method is applicable in current–population based –clinical practice as well as
in personalized health applications. In this study, SHM was successfully applied for diagnosis of several orphan diseases as
well as detection of metabotypic abnormalities related to diet and drug intake.
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Introduction
Metabolomics is becoming increasingly important in a whole
range of healthcare-related fields such as disease prevention,
diagnosis and intervention, and studies of the impact of diet and
nutrition on various forms of illness [1–3]. In such studies, the
metabolic phenotype or metabotype of individuals is studied. The
metabotype is a characteristic metabolite profile that depends on
the interplay between genes and environmental factors such as
diet, lifestyle, gut microbial composition, and – in patients –
medication. This profile varies greatly between individuals and
populations. Therefore, metabotyping has applications in popula-
tion-based and personalized medicine [1,4]. For example, various
(subtle) abnormalities in the metabotype have been related to
cancer states, diabetes, cardiovascular diseases, neurological
diseases and inborn errors of metabolism (IEM) [1,3,5,6].
Commonly, the metabotype of an individual is measured from
easily accessible biofluids such as urine or serum, or more seldom
from tissue [2]. Typically, untargeted metabolomics techniques
such as 1H nuclear magnetic resonance (NMR) spectroscopy or
mass-spectrometric methods are used for this purpose [2,7,8].
These techniques can measure a wide range of metabolites
simultaneously and generate a multivariate profile of metabolites
present in the sample. Due to the complex nature of the
metabolome in biofluids multivariate data analysis is often
required to interpret the acquired data and detect metabolic
abnormalities. Most studies deal with classification problems such
as disease diagnosis (healthy versus a specific disease) [3,9]. During
data analysis, such problems are commonly tackled as a two-class or
a one-class problem.
Two-class classification strategies aim to model the metabolic
differences between groups of healthy and diseased individuals.
These differences are grouped in a metabolic pattern or biomarker
representing the abnormalities related to the disease. Typically
used methods for two-class classification are orthogonal projection
to latent structure (OPLS) and linear discriminant analysis (LDA)
[9]. More challenging problems are generally tackled using non-
linear approaches such as SVM, K-PLS or Random Forests
[10,11]. In contrast, one-class classification methods focus on the
similarities that are encountered within the diseased group. This
results in a characterization of the expected metabotypes for a
specific disease (e.g. an average metabotype and expected
metabolic variation). Here, the most commonly used technique
is SIMCA [9]. For both classification strategies, a diagnosis is
made by matching the metabotype of a patient against the result of
the model, being this biomarker or expected metabotype.
Both strategies focus on groups of patients with one specific
disease. This might be impractical in a clinical setting for three
reasons. First, it is not realistic to construct a statistically valid
model for rare or orphan diseases. Such diseases are defined in the
United States as any disease that affects fewer than 200000
individuals, and in the European Community as any disease that
affects fewer than 5 in 10000 individuals [12]. Some rare diseases
have less than a dozen known cases. In other words, the number of
potential patients to base the model on is too low. Secondly, even if
orphan diseases are ignored, each disease requires its own specific
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model. Thirdly, unknown metabolic perturbations, for instance
caused by unknown diseases, may not be detected or falsely
interpreted.
Interestingly, similar problems are encountered when monitor-
ing industrial processes. Analogous to disease diagnosis one wants
to know whether or not the process is in-control (healthy); if not, a
known or unknown rare event (a disease) has occurred that may
affect product quality. So-called statistical process control (SPC)
techniques have been developed to detect all of these events as
early as possible [13]. Due to the success of SPC, we propose here
to adapt these strategies and apply the method on metabolome
profiles of body fluids with the aim of diagnosing the disease of a
patient. This provides a new tool for diagnostic support: statistical
health monitoring (SHM).
In SHM, the so-called normal operating conditions (NOC) of
healthy people are defined. NOC is a term that is often used in
SPCA. In this case it basically means that a one-class classifier is
used to model the expected metabotypes of healthy individuals.
The NOC should therefore represent the average metabotype of a
population and the inherent (normal) variation present in this
population e.g. due to difference in life style. Next, the metabotype
of a patient is compared to NOC. Deviations from NOC such as
abnormal metabolite concentrations or abnormal patterns of
concentrations are indicated by the method. Subsequently, this
information – a (disease) biomarker for this individual patient –
can be used for diagnosis. The fact that only data of healthy people
is required to construct the SHM model is a tremendous
advantage of this approach. Because of this, SHM is not disease
specific and can be used for diagnosis of rare diseases.
As a case study we applied SHM for diagnosis of a family of
orphan diseases, namely inborn errors of metabolism. IEM
comprise a substantial group of rare genetic diseases that can be
diagnosed by NMR spectroscopy in combination with visual
inspection of the data [5]. Because of the complex structure of the
spectra this can be quite a challenge. Moreover, such an approach
is extremely time-consuming and quite subjective. The proposed
SHM approach may make the diagnosis of IEM easier and
objective. Additionally, it will be shown that, depending on how
the NOC are defined, SHM can also detect metabolic abnormal-
ities related to diet and medication.
The next section will outline the concept of SHM and
mathematic background. In the remaining sections the properties
of SHM are discussed based on application of SHM to the case
study example involving IEM.
Theory of Statistical Health Monitoring
In SHM the metabotype of an individual is compared to that of
healthy people in a multivariate manner. Abnormal metabolite
concentrations, or abnormal patterns of concentrations, are
indicated by the method. This is achieved in two steps. In this
first step – detection of abnormal metabotypes – the metabotype of
an individual is matched against NOC and marked as normal or
possibly abnormal. The abnormal metabolites are identified in a
second step.
Detection of abnormal metabotypes
The first step in SHM is to select samples that represent the
NOC of healthy humans well. From now on we will refer to these
samples as normal or NOC samples. The choice of NOC samples
should reflect the goal of the SHM analysis. For example, if the
goal is purely to detect abnormalities related to disease, the NOC
set can include healthy individuals who recently took medication.
However, if one also wants to detect abnormal metabolites related
to drugs, these individuals should not be included. Additionally,
the demographics of the NOC samples and the expected patients
should be as similar as possible. For example, if a patient has a
completely different lifestyle compared to the NOC samples, many
metabolites may falsely be marked as abnormal. However, if the
demographics are too loosely specified, the limit of detection of the
SHM model will be negatively affected. We will further elaborate
on this important aspect in the discussion section.
The NOC samples are stored in data table (Xh). Each row inXh
contains the metabotype information from one healthy individual.
Each column corresponds to a measured feature, e.g. a chemical
shift value in an NMR spectrum. The data is centred to zero mean
before starting the statistical analysis. Often it is also useful to scale
the data – e.g. to unit variance – to ensure that each feature has
equal chance to influence the model.
Principal component analysis (PCA) is used to describe the
NOC data [13]:
Xh~ThP
T
hzEh ð1Þ
Here, ThPh
T is the part of the model that describes the
structural metabolic variation between the NOC samples, while
matrix Eh only contains residuals or non-structural variation. Th
describes the systematic metabolic differences or variation between
the NOC samples. The columns in Ph, or factors, are the actual
model. The factors are descriptors that indicate in which measured
features the systematic differences occur. A property of the factors
is that they are ordered by importance: the first ‘‘explains’’ most
variation, followed by the second, etc. At some point the
remaining factors only describe noise. These factors are not
included in the model.
To determine whether someone is possibly diseased, the
metabotype information from this individual (xnew) is evaluated
using the constructed model:
xnew~tnewP
T
hzenew ð2Þ
Note that tnewPh
T describes which part of the individual’s
metabotype is in accordance with the metabotypes that are
expected for NOC samples. If an individual is similar to the
normal samples, this prediction should capture his/her complete
metabotype. In this case, the error enew should be small and fall in
the range of the error of the NOC samples. Therefore, abnormal
metabotypes can be detected by inspection of the size of enew. In
industrial process control, the so-called Q-statistic is used for this
purpose [13]:
Q~ enewk k2 ð Þ
A sample with a high Q-value corresponds to a metabotype that
either contains abnormal metabolite(s) or abnormal metabolite
concentrations that break the normal between-metabolites corre-
lation pattern. The metabotype of an individual is marked as
abnormal if the value for Q exceeds the significance limit given by
Qa [14]:
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where the parameters of the approximation are defined as
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~
L is the covariance matrix of Eh, and za is the standardized
normal variable with (12a) confidence limit, having the same sign
as h0 [14].
To summarize, for a measured metabotype (xnew) the PCA
model (tnewPh
T) is used to predict what this metabotype would
look like if the individual was an NOC sample. The larger the
difference between predicted and measured metabotype (enew) the
more likely the metabotype is to be abnormal. The size of this
difference is expressed via the Q-statistic. An example of SHM
when monitoring 2 metabolites is presented in File S1.
Identification of abnormal metabolites
The second step in SHM is to detect the abnormal metabolites
that caused the deviation from NOC. A clinical practitioner can
use this information for example for disease diagnosis, possibly via
a database search.
Since the Q-statistic should detect all deviations from NOC, the
contribution of measured features to this statistic should be
investigated. For this purpose, the value for Q is decomposed into
per feature contributions. Here, we used partial decomposition
[15]:
Q~ enewk k2~xnew I{PhPTh
 
xTnew~
XK
i~1
xnew I{PhP
T
h
 
jij
T
i x
T
new~
XK
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ð Þ
where I is the identity matrix and ji is the i th column of the
identity matrix. Index i and K indicate a specific feature and the
total number of measured features, respectively. The contribution
of the measured value in feature i to Q equals qi. High values
indicate abnormal behaviour of this particular feature. However,
the contribution of each feature in the NOC data should be taken
into account as well: a large contribution of a feature becomes less
meaningful if such contribution values were also observed for the
NOC samples. Therefore, all contributions were studied relatively
to the variance of the NOC residuals Eh [15]:
rqi~
qi
~Li,i
Where ~Li,i indicates the element in the i th row and column of
~
L.
The set of relative contributions for all features will be referred
to as a personal health profile or personal biomarker.
Method and Materials
Data
To assess the value of SHM for disease diagnosis, a set of urine
samples of 193 healthy children and a set of 24 patients was
measured using proton NMR spectroscopy. Eighteen patients
were known to suffer from one of seven different IEM. For the
other six patients, no IEM was diagnosed, but their metabotypes
contained commonly prescribed drugs such as depakine and sabril.
More details regarding the healthy and patient samples are
specified in Tables 1 and 2, respectively. Note that a subject had to
be between 4–12 years old to participate in this study and be of
Dutch ancestry. An equal amount of males and females were
selected.No other selection criteria such as lifestyle and diet were
imposed.
The urine samples were centrifuged before analysis. A volume
of 70 ml of a 20.2 mmol/l trimethylsilyl-2,2,3,3-tetradeuterium-
propionic acid (TSP, sodium salt; Aldrich) 2H2O solution was
added to 700 ml of urine as a chemical shift reference (d=0.00)
and as a lock signal. The pH of the urine was adjusted to
2.5060.05 with HCl. Finally, 650 ml of the sample was placed into
a 5-mm NMR tube (Wilmad Royal Imperial; Wilmad LabGlass,
USA).
Table 1. Abnormal compounds present in urine 1D 1H-NMR spectra from the healthy individuals.
Compound CS (ppm); multiplicity Origin
Acesulfame 2.11d; 5.67q Artificial sweetener
Acetaminophen 2.15s; 6.90d; 7.25d Paracetamol
A-glucuronide* 2.16s; 5.12d; 7.13d; 7.34d Paracetamol
A-L-cysteinyl* 2.15s; 6.99d; 7.51d Paracetamol
A-N-acetyl-L-cysteinyl* 1.84s; 2.14s; 6.93d; 7.42d Paracetamol
A-Sulphate* 2.17s; 7.45d; 7.31d Paracetamol
Cyclamate 1.53–2.06m Artificial sweetener
Mannitol 3.6–3.8v Sweetener
N-Methylhydantoin 2.92s; 4.08s Bacteria
TMA-oxide 3.54s Fish meal
The metabolites were identified by comparison of the abnormal resonances to a database of NMR spectra of model compounds [5]. In cases where the overlap of
resonances in the 1D spectrum was quite severe, 2D COSY NMR experiments were used to provide additional information and confirm that the metabolite identification
based on the 1D spectrum was correct.
*Spectrum not completed interpreted; s = singlet; d = doublet; t = triplet; q = quartet; m =multiplet; v = various multipets.
A = Acetaminophen; TMA= Trimethylamine.
doi:10.1371/journal.pone.0092452.t001
Statistical Health Monitoring
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e92452
ð Þ
ð Þ5
6
7
8
1H NMR spectra were ubtained using a Bruker 500 MHz
spectrometer (pulse angle 90u, delay time 4 s, number of scans
256, temperature 298 K). The water resonance was suppressed by
gated irradiation centred on the water frequency. Shimming was
performed automatically on each sample prior to the data
acquisition using the TopShim method from Bruker BioSpin.The
phase and baseline were corrected manually.
The regions 0.2–4.7 ppm and 5.0–10.0 ppm were selected for
further analysis in Matlab 7.14 (Mathworks, Natick, Massachu-
setts, U.S.A.). Next, the urine profiles were normalized to the
creatinine signal to correct for dilution effects. Equidistant binning
with a bin size of 0.04 ppm was used to reduce the dimension of
the normalized data from 30888 to 246 variables. Finally, the data
was centred to zero mean and scaled to unit variance.
For some samples (see below), 2D COSY NMR spectra were
also recorded for extra spectral information. The spectra were
recorded at 500 MHz using 4 k data points in F2 and a spectral
with of 6002 Hz. For all samples, 256 increments and 16 scans per
increment were used. The TR was 2 s, during which the water
resonance was presaturated. Prior to Fourier transformation, a
since function was applied in both time domains.
Ethics statement
The medical ethical committee of the Radboud University
Medical Centre in Nijmegen, The Netherlands, approved the
study protocol. Informed verbal parental consent was obtained for
all volunteers. At that time consultation of the medical ethical
committee of the Radboud University Medical Centre in
Nijmegen, The Netherlands resulted in the advice to ask the
collaboration of the parents/caretakers of the children via an
information letter explicitly stating that their collaboration was on
a voluntary basis and that all samples would be fully anonymized
and that all samples would be destroyed at the latest 5 years after
the sample collection.
SHM model construction and validation
First, the raw NMR spectra of the 193 healthy individuals were
extensively screened by an experienced clinical practitioner to rule
out any abnormal metabolic patterns in these samples. Seventeen
samples with abnormal patterns related to dietary influences and
drug intake were identified. These samples were marked as
abnormal and used to validate the SHM approach since detection
of abnormal patterns due to diet and drugs is in principle no
different from detection of abnormalities related to a disease.
Additionally, the set of 24 patients was used for validation. In all
samples, the abnormal metabolites were identified by the clinical
practitioner by comparison of the abnormal resonances to a
database of NMR spectra of model compounds [5]. In cases where
the overlap of resonances in the 1D spectra was quite severe, 2D
COSY NMR experiments were used to provide additional
information and confirm that the metabolite identification based
on the 1D spectra was correct.
The SHM model was constructed on the basis of 120 training
samples that were selected from the remaining set of 176 binned
1H NMR spectra of normal (healthy) individuals by the Kennard
Stone algorithm [16]. The optimal number of factors in the PCA
model was determined by a bootstrapping algorithm called
NUMFACT [17]. In essence, the PCA factors determined for
each resampling were compared for changes. Factors which
changed significantly from one resampling to the next were
probably due to noise and excluded from the model.
Validation of identification of abnormal metabolites was
performed by applying the left-out 56 healthy; 17 healthy, but
abnormal; and 25 patient samples to the SHM model. An imposed
significance limit (a) of 5% was used. Note that centring and
scaling of the test data was based on the feature means and
standard deviations of the training data.
All analysis was performed using in-house developed algorithms.
Bootstrapping to estimate the number of factors in PCA was
performed with PLS_Toolbox 6.7.1 [18].
Table 2. Abnormal compounds present in urine 1D 1H-NMR spectra from the patients.
Compound CS (ppm); multiplicity IEM/Orign
Arginine 1.69m; 1.92m; 3.24q; 3.85t Cystinuria
4-Amino-5-hexenoic acid 1.94m; 2.08m; 2.46m; 5.47m; 5.80m Medication: Sabril
Dihydroxycholenic acid 0.67s; 0.80–0.94v 3b-Hydroxy-D5-C27-steroid dehydrogenase deficiency
Formiminoglutamic acid 2.00–2.22v; 2.47t Formiminotransferase deficiency
Homogentisic acid 3.64s; 6.78m Alkaptonuria
Hydantoin-5-propionic acid 2.00–2.22v; 2.51t Formiminotransferase deficiency
3-Hydroxyisovaleric acid 1.33s; 2.55s Isovaleric aciduria 3MCC-deficiency
Isovalerylglycine 0.94d; 2.02m; 2.18d; 3.94d Isovaleric aciduria
Lysine 1.47m; 1.72m; 1.92m; 3.01t; 3.77t Cystinuria
3-Methylcrotonylglycine 1.86d; 2.03d; 3.97d; 5.78m 3MCC-deficiency
2-oxo-1-pyrrolidine acetamide 2.10m; 2.48t; 3.52t; 4.01s Medication: Piracetam
5-Oxoproline 2.20m; 2.43m; 2.55m; 4.36m 5-Oxoprolinuria
Taurine 3.27t; 3.43t(wide due to exchange) Unknown; possibly nutrition
Trihydroxycholenic acid 0.73s; 0.80–0.94v 3b-Hydroxy-D5-C27-steroid dehydrogenase deficiency
Valproic acid 0.88t; 1.30m; 1.50m; 2.44m Medication: Depakine
The metabolites were identified by comparison of the abnormal resonances to a database of NMR spectra of model compounds [5]. In cases where the overlap of
resonances in the 1D spectrum was quite severe, 2D COSY NMR experiments were used to provide additional information and confirm that the metabolite identification
based on the 1D spectrum was correct.
*Spectrum not completed interpreted; s = singlet; d = doublet; t = triplet; q = quartet; m =multiplet; v = various multipets.
3MCC=3-Methylcrotonyl CoA carboxylase.
doi:10.1371/journal.pone.0092452.t002
Statistical Health Monitoring
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Results
Inspection of the 1H NMR data: current clinical practice
The data was first analysed according to current clinical
practice, namely by visual inspection and by means of PCA
scoreplots. This inspection was required to select the NOC
samples (healthy individuals) on which the SHM model could be
trained.
A clinical expert visually inspected the NMR data of the 193
healthy children and the 24 patients. Ten exogenous metabolites
related to diet or drug intake were observed in the set of 193
children. More details are specified in Table 1. Seventeen samples
contained metabolites related to bacteria, a fish meal, paraceta-
mol, or cyclamate. The artificial sweeteners Acesulfame K and
mannitol were present in the metabotype of such a large number
of healthy individuals that they were not marked as abnormal
metabolites. Fifteen abnormal metabolites were observed in the 24
patient samples. These were related to 7 IEM (18 patients) as well
as medication (6 patients). More details are specified in Table 2.
In figure 1, a PCA scoreplot of all samples is shown (autoscaled
data). The samples were coloured according to the observations
made by the clinical expert. Clearly, many abnormal metabotypes
could not be distinguished from healthy samples this way.
Alternative colourings of the plot indicated no trends related to
age, gender or other demographics either.
Statistical health monitoring
The SHM model was constructed on the basis of 120 healthy
metabotypes. The clinical expert had not detected any of the
exogenous metabolites listed in table 1 in these samples, except for
the articial sweeteners Acesulfame and mannitol. This means that
future samples that contain exogenous metabolites related to fish,
paracetamol intake, etc will be marked as abnormal by the model
even if they are healthy. This can be undesirable if the sole
purpose of the SHM model is disease diagnosis. We will further
elaborate upon this choice of NOC samples in the discussion.
Eighty-three percent of the total variation in the NOC data was
estimated to be systematic by NUMFACT. This variation was
modelled by the first 16 factors. Next, the metabotype of
the validation samples was automatically inspected using the
constructed SHM model. As shown in figure 2, Q-values of the
abnormal metabotypes were clearly larger compared to the
normal metabotypes. Using the imposed significance limit of
5%, all normal and abnormal metabotypes were correctly
identified. Note that the cut-off point Q5% to mark a patient’s
metabotype as abnormal was completely based on the training
samples (equation 4).
The 17% variance left out of the model must correspond to
individual variations, which did not necessarily belong to the NOC
of the whole group. This unexplained variance partly re-appeared
as Q contribution. Therefore, metabotypes of normal individuals
did not have zero contribution for every feature. Statistically
speaking, with the chosen significance level 5% of the samples that
are within NOC are expected to be incorrectly marked as
abnormal (i.e. 3 individuals). In this case all normal individuals
were correctly detected which is related to size of our test cohort.
For metabotypes marked as abnormal, the abnormal metabo-
lites were identified via the relative feature contributions to Q. The
set of relative contributions can be considered as a personal
biomarker for that individual since they highlight how and how
much this individual is different from NOC. The contribution can
be visualized in a so-called contribution plot which is commonly
done in industrial process control, or in the original NMR
spectrum to integrate SHM in current clinical practice. In a
contribution plot the relative contribution is plotted against the
chemical shift value. Three examples are presented in figures 3a, c,
and e. In each figure, high peaks relative to the baseline indicate
resonances that were abnormal with respect to NOC. An
advantage of contribution plots is that features with a large
contribution are easy to identify, even if they have a low intensity
in the original NMR spectrum (e.g. the resonances between 9.6–
9.8 ppm in figures 3e and 3f). In contrast to contribution plots,
visualization in the NMR spectrum itself allows the user to make
combined use of contribution values as well as NMR knowledge
such as multiplet structure to make a diagnosis. As shown in
figures 3b, d, and f, the contribution values are colour coded in this
type of visualization.
The abnormal metabotypes were further inspected using both
representations of the relative contribution. All IEM, were correctly
diagnosed this way. Similarly, all abnormalities related to diet and
the different types of medication were correctly identified. Most
IEMwere diagnosed via key resonances – biomarkers relating to the
Figure 1. PCA scoreplot of the autoscaled data. Note that the
points are coloured according to the observations made by a clinical
expert as healthy; healthy, but exogenous metabolites were present;
patients diagnosed with IEM; and other patients.
doi:10.1371/journal.pone.0092452.g001
Figure 2. Q-values obtained by statistical health monitoring for
56 healthy and 42 abnormal metabotypes.
doi:10.1371/journal.pone.0092452.g002
Statistical Health Monitoring
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Figure 3. Feature contributions visualized in a contribution plot and the original NMR spectra for three abnormal metabotypes. The
abnormal metabolites are related to (A, B) high concentrations of taurine, (C, D) alkaptonuria, and (D, E) paracetamol comsumption. The arrows
indicate the resonance corresponding to the middle of a bin. Each bin had a width of 0.04 ppm.
doi:10.1371/journal.pone.0092452.g003
Statistical Health Monitoring
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specific IEM; not always were all relevant biomarker resonances for
a specific IEM marked as abnormal. This is similar to visual
inspection of the data: resonances with a high degree of splitting or
overlap cannot be discerned from noise in 1D spectra.
In order to illustrate the principles of relative contributions and
the procedure to follow to establish a potential diagnostic better,
we will describe the three examples in figure 3 in more detail
below. The complexity of these examples is progressively rising in
terms of spectral interpretation meaning that correct identification
by SHM is more challenging.
Case 1. The first example is considered relatively simple
because only two resonances are involved. As shown in figure 3a,
SHM clearly marked two resonances at 3.27 and 3.43 ppm as
abnormal: the relative contribution was much larger compared to
the contribution of other resonances. Similar to visual inspection
of the data, the metabolite corresponding to these abnormal
resonances was identified by comparison of the resonances to a
database of NMR spectra of model compounds. These particular
two resonances correspond to taurine indicating that the
metabotype of this patient contained abnormally high concentra-
tions of taurine. This was confirmed by visual inspection of the
spectrum by the clinical expert. At the moment the cause of the
high concentrations of taurine in the metabotype of this patient is
unknown. Perhaps, the abnormality can be related to diet, e.g.
consumption of energy drinks.
Case 2. The contribution plot of this patient also showed two
resonances that were abnormal: a singlet at 3.64 ppm and a
multiplet at 6.78 ppm (figures 3c and 3d). However, inspection of
this plot was more difficult compared to case 1. The multiplet was
much easier to detect compared to the singlet because the NMR
spectra of healthy individuals did not contain much signal around
6.78 ppm. Therefore, the relative contributions of this multiplet
were very large. In contrast, the singlet at 3.64 ppm was positioned
in a crowded region of the spectra resulting in much lower
contribution values. However, compared to the contributions at
the surrounding chemical shifts, the singlet at 3.64 was still clearly
abnormal. This shows that inspection of contribution plots should
not only focus on the absolute value of the contributions, but on
their size relative to the contribution that is observed for most
chemical shifts. One could say that for each individual the ‘‘Q
baseline’’ must be used to determine if a particular peak is
abnormal or not. The abnormal singlet at 3.64 ppm and the
multiplet at 6.78 ppm indicated that the metabotype of this
individual contained a large concentration of homogentisic acid
[5]. Thanks to this, the patient was diagnosed with the IEM
alkaptonuria. Alkaptonuria is caused by a deficiency of the enzyme
homogentisic acid oxidase in tyrosine catabolism [5]. This results
in high concentrations of homogentisic acid in the urine of such a
patient.
Case 3. As shown in figure 3e, eight regions in the NMR
spectrum of this individual had abnormal contributions. Similar to
case 2, the contributions of the relevant resonances again differed
by orders of magnitude.
Comparison of the abnormal regions to spectra of model
compounds clearly indicated that the metabolites acetaminophen,
acetaminophen-glucuronide, and acetaminophen-sulphate were
present in high concentrations (see table 1). This is caused by
consumption of paracetamol by this individual. As shown in
Table 1, this drug can actually be detected in urine via abnormal
concentrations of five metabolites. A number of these metabolites
will be visible in the NMR spectrum depending on how the drug
was metabolized. In this case no high Q-values were observed at
resonances 1.84, 6.99, and 7.51 ppm. This indicates that the
compounds A-N-acetyl-L-cysteinyl and A-L-cysteinyl were either
present in very low concentration, or that in this particular case
paracetamol was not metabolised into these metabolites. This was
confirmed by visual inspection of the NMR spectrum. Due to the
large number of resonances involved, identification of paracetamol
intake via SHM is considered more difficult compared to the
previous two cases. Additionally, the intensities of the resonances
involved are much lower which makes diagnosis even more
difficult.
Note that for all individuals who consumed paracetamol, the
resonances around 9.8 ppm were also marked as abnormal. These
resonances have not been described in literature. However, by
means of a simulated NMR spectrum of paracetamol in the
Bruker software we ascribe these resonances to NH-groups in the
molecule.
Discussion
In this study, SHM was introduced as a valuable tool for
diagnosis of a multitude of possible (rare) diseases. The method
was successfully applied in a case study involving diagnosis of
several IEM as well as metabolic abnormalities related to drug
consumption and diet.
First, the metabotype of each individual was marked as normal
or abnormal: 100% of the ‘‘healthy’’ and 100% of the abnormal
metabotypes were correctly identified. Next, it was shown that
feature contributions can be used to identify the abnormal
metabolites. The contributions are very easy to calculate without
prior knowledge. Prior knowledge, however, is required to
interpret them and relate the abnormal features to a disease.
Therefore, SHM should be regarded as a decision support tool for
diagnosis. In case of rare diseases, SHM is the only tool available
to detect the abnormalities. In case of more common diseases, the
SHM-based metabotype screening could be followed by more
classical targeted approaches (e.g. a two-class classifier) to confirm
the diagnosis.
The first step of SHM, detection of abnormal metabotypes in a
multivariate fashion, is functioning in a reliable way. The second
step concerns identification of the abnormality. This identification
relies on a univariate evaluation of the individual contributions of
each feature or measured signal to Q. These contributions should
be studied with some caution due to the so-called smearing effect:
contributions from abnormal features can propagate to other
features meaning that fault free features can show increased
contribution [15]. This a well-known issue in industrial process
control that has been greatly discussed in literature [13]. The
smearing effect is a direct consequence of the fact that an SHM
model is constructed on the basis of normal metabotypes. Because
of this the model is very well able to detect when a metabotype is
abnormal. However, when the abnormal metabolites are identified
via the Q-statistic again information from the normal (NOC)
individuals has to be used (see equation 7). The model assumes
that the correlations between metabolites in the abnormal
metabotype are the same as those encountered in the NOC
samples. This doesn’t have to be the case. This imperfect
assumption may lead to some false positives i.e. some metabolites
can be marked as abnormal while they are not. Unfortunately, the
smearing effect cannot be avoided. In this study, the smearing
effect was minimized by using partial decomposition of the Q-
statistic, instead of the commonly used complete decomposition
method. This ensures that the contribution of an abnormal feature
will always be greater than the contribution given to the ‘‘good’’
feature [15].
Some works in the process control literature suggest the use of
control limits for determining the significant feature contributions.
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However, this should be discouraged since the (biological)
unrelated features might also show an increased contribution
due to the smearing effect [15]. Therefore, we prefer to rely on
human expertise by visually inspecting the contribution plots.
Selection of NOC samples is a critical step in the
construction of an SHM model. The proposed method detects
deviations from these normal samples. This deviation can be
related to disease, but also a healthy sample with a deviation
that is not present in the NOC set – e.g. the paracetamol
example presented in case study 3. When disease diagnosis is
the goal of the SHM model, examples such as case 3 are false
positives. As shown in figure 1, the patient samples differed
more from the NOC samples (the healthy group) compared to
the group of healthy samples that contained exogenous
metabolites. This was the main reason why the latter group
was not included in NOC: we wanted to investigate if SHM
was also able to detect these smaller deviations from NOC.
This group should be included in NOC, however, if the user
only wants to detect metabolites related to disease. Therefore,
we also briefly investigated this disease diagnosis model. A
direct consequence of the fact that the NOC now contained
extra inter-individual variation due to diet and medication was
that the cut-off value for Q (equation 4) was increased. This
means that samples will less quickly be marked as abnormal,
increasing the chance of false negatives. In this case, however,
all patient samples were still correctly diagnosed. In contrast to
the SHM model presented in the results section, all samples
with metabolites related to medication and drugs were now
marked as normal. In this feasibility study, the NOC set was a
small population of healthy children. These samples matched
in age and ancestry to the expected IEM patients. No
restrictions on factors such as lifestyle were imposed to ensure
enough diversity within the NOC set so that it is representative
of future patient samples. However, due to the size of our
cohort most likely not all possible factors such as all types of
medication were included in NOC. We expect that a much
larger cohort of randomly selected NOC samples would
contain most of the common diets; types of medication; and
other factors, thereby avoiding the occurrence of false positives
related to this. Additionally, if false positives occur later on, the
NOC set can be updated with these samples. Note that the
cohort should match the expected demographics of the
patients are closely as possible since the larger the biological
variation of the NOC samples the more difficult it will be to
detect a subtle abnormality related to disease.
When working with large cohorts of NOC samples, an
interesting research line would be to see if sub-populations of
normal individuals with completely different characteristics due to
e.g. environmental factors can be identified. Each sub-population
has its own NOC. In such a case, a SIMCA-like model structure
where a separate SHM model is constructed for each population
seems more appropriate compared to one general model that was
used in the present study. Matching new samples only against
NOC of the correct sub-group could greatly enhance the power of
the SHM model for disease diagnosis. If the subpopulations are
unknown, perhaps a clustering approach such as mixture
modelling can be used to define them.
Three additional future development lines can be defined for
SHM: (1) connection of SHM output to a disease database, (2)
development of personalized health control, and (3) application of
SHM in clinical trials. The first research line could be
implemented in SHM in the form of a database of known disease
which would automatically link the abnormalities detected with a
list of potential diseases.
The second perspective is to define NOC at an individual level
instead of a population or sub-group based one. To do so,
longitudinal metabotyping experiments should be performed. The
SHM model would then very precisely describe the NOC
metabotype profile because no intra-individual differences have
to be taken into account. In consequence, SHM would be able to
detect more subtle abnormalities. An additional advantage of
longitudinal studies for detection of abnormal metabotypes is that
the user can accumulate information from a series of measure-
ments. One could check whether measurements appear randomly
distributed between the control limits or if a structure is appearing,
signalling the start of a deviation from NOC. Such tests may
greatly improve the power of SHM for disease detection.
Identification of the specific abnormality may be improved by
studying contributions relative to the last k timepoints instead of all
NOC samples. The abnormal metabotype should be most similar
to the last metabotypes that were measured before the individual
became ill.
In this study, NMR was used to assess the metabotype of each
individual because it is a very stable technique with a detection
limit in the low micromolar range. This technique has been used
routinely for over 20 years in Radboud University Medical Centre
in Nijmegen to diagnose IEM. Although NMR is a valuable
analytical platform to diagnose IEM, it is not necessarily the best
technique for other diseases. Other data types such as results of
classical blood tests or more advanced measurements such as 2D-
NMR and LC-MS should be used if they are known to provide
more relevant information. In principle, SHM can be applied to
any type of data. For each application it is important to take into
account the structure of the data and adjust the model accordingly.
Here, PCA was used to describe healthy metabotypes. Multiway
data coming from 2D-NMR or LC-MS could be evaluated using a
PARAFAC or Tucker3 structure [19]. Because SHM can be
applied to any data type, it will most likely not only find
application in metabolomics, but also in other fields such as
proteomics or genomics.
Conclusion
Due to the complex nature of metabolomics data, multivar-
iate statistics are required interpret the data. Unfortunately,
current multivariate tools can only diagnose diseases in a
targeted fashion; a separate model is required for each disease.
Additionally, such tools are not always applicable to rare or
orphan diseases. Abnormal metabotypes can sometimes be
detected in an untargeted fashion by visual comparison of the
data. However, detection of subtle abnormalities and abnor-
mal patterns is extremely subjective and time-consuming. An
alternative approach, SHM, was proposed in this study.
In SHM, the metabotype of an individual is compared to
normal (healthy) metabotypes in a multivariate manner. Any
abnormal patterns are indicated by the method. Subsequently, this
information can be used for diagnosis. In this study, SHM was
successfully applied for diagnosis of various metabotypic abnor-
malities related to diet, drug intake and IEM.
SHM is a general method that is not only applicable to
metabolomics data. Additionally, the method offers perspectives in
the framework of personalized health.
Supporting Information
File S1 An example of SHM when monitoring 2
metabolites is presented as supporting material.
(DOCX)
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